Top

Published in:

01-06-2017 | Original Research

Information Topics of Greatest Interest for Return of Genome Sequencing Results among Women Diagnosed with Breast Cancer at a Young Age

Authors: Joann Seo, Jennifer Ivanovich, Melody S. Goodman, Barbara B. Biesecker, Kimberly A. Kaphingst

Published in: Journal of Genetic Counseling | Issue 3/2017

Abstract

We investigated what information women diagnosed with breast cancer at a young age would want to learn when genome sequencing results are returned. We conducted 60 semi-structured interviews with women diagnosed with breast cancer at age 40 or younger. We examined what specific information participants would want to learn across result types and for each type of result, as well as how much information they would want. Genome sequencing was not offered to participants as part of the study. Two coders independently coded interview transcripts; analysis was conducted using NVivo10. Across result types, participants wanted to learn about health implications, risk and prevalence in quantitative terms, causes of variants, and causes of diseases. Participants wanted to learn actionable information for variants affecting risk of preventable or treatable disease, medication response, and carrier status. The amount of desired information differed for variants affecting risk of unpreventable or untreatable disease, with uncertain significance, and not health-related. Women diagnosed with breast cancer at a young age recognize the value of genome sequencing results in identifying potential causes and effective treatments and expressed interest in using the information to help relatives and to further understand their other health risks. Our findings can inform the development of effective feedback strategies for genome sequencing that meet patients’ information needs and preferences.

Anders, C. K., Hsu, D. S., Broadwater, G., Acharya, C. R., Foekens, J. A., Zhang, Y., et al. (2008). Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Journal of Clinical Oncology, 26(20), 3324–3330. doi:10.1200/jco.2007.14.2471.CrossRefPubMed

Anders, C. K., Johnson, R., Litton, J., Phillips, M., & Bleyer, A. (2009). Breast cancer before age 40 years. Seminars in Oncology, 36(3), 237–249. doi:10.1053/j.seminoncol.2009.03.001.CrossRefPubMedPubMedCentral

Assi, H. A., Khoury, K. E., Dbouk, H., Khalil, L. E., Mouhieddine, T. H., & El Saghir, N. S. (2013). Epidemiology and prognosis of breast cancer in young women. Journal of Thoracic Disease, 5(Suppl 1), S2–S8. doi:10.3978/j.issn.2072-1439.2013.05.24.PubMedPubMedCentral

Biesecker, L. G., & Green, R. C. (2014). Diagnostic clinical genome and exome sequencing. The New England Journal of Medicine, 370(25), 2418–2425. doi:10.1056/NEJMra1312543.CrossRefPubMed

Bonadona, V., Sinilnikova, O. M., Chopin, S., Antoniou, A. C., Mignotte, H., Mathevet, P., et al. (2005). Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes, Chromosomes & Cancer, 43(4), 404–413. doi:10.1002/gcc.20199.CrossRef

Bredenoord, A. L., Kroes, H. Y., Cuppen, E., Parker, M., & van Delden, J. J. (2011). Disclosure of individual genetic data to research participants: the debate reconsidered. Trends in Genetics, 27(2), 41–47. doi:10.1016/j.tig.2010.11.004.CrossRefPubMed

Caulfield, T., McGuire, A. L., Cho, M., Buchanan, J. A., Burgess, M. M., Danilczyk, U., et al. (2008). Research ethics recommendations for whole-genome research: consensus statement. PLoS Biology, 6(3), e73. doi:10.1371/journal.pbio.0060073.CrossRefPubMedPubMedCentral

Christenhusz, G. M., Devriendt, K., Peeters, H., Van Esch, H., & Dierickx, K. (2014). The communication of secondary variants: interviews with parents whose children have undergone array-CGH testing. Clinical Genetics, 86(3), 207–216. doi:10.1111/cge.12354.CrossRefPubMed

Crouch, J., Yu, J. H., Shankar, A. G., & Tabor, H. K. (2015). “We don’t know her history, her background”: adoptive parents’ perspectives on whole genome sequencing results. Journal of Genetic Counseling, 24(1), 67–77. doi:10.1007/s10897-014-9738-z.CrossRefPubMed

Cybulski, C., Wokolorczyk, D., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., et al. (2011). Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. Journal of Clinical Oncology, 29(28), 3747–3752. doi:10.1200/jco.2010.34.0778.CrossRefPubMed

Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., et al. (2015). Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncology, 1(7), 943–951. doi:10.1001/jamaoncol.2015.2690.CrossRefPubMed

Dressler, L. G. (2009a). Biobanking and disclosure of research results: Addressing the tension between professional boundaries and moral intuition. In J. H. Solbakk, S. Holm, & B. Hofmann (Eds.), The ethics of research biobanking (pp. 85–99). New York: Springer.CrossRef

Dressler, L. G. (2009b). Disclosure of research results from cancer genomic studies: state of the science. Clinical Cancer Research, 15(13), 4270–4276. doi:10.1158/1078-0432.CCR-08-3067.CrossRefPubMed

Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., & Mardis, E. R. (2012). Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 486(7403), 353–360. doi:10.1038/nature11143.PubMedPubMedCentral

Facio, F. M., Brooks, S., Loewenstein, J., Green, S., Biesecker, L. G., & Biesecker, B. B. (2011). Motivators for participation in a whole-genome sequencing study: implications for translational genomics research. European Journal of Human Genetics, 19(12), 1213–1217. doi:10.1038/ejhg.2011.123.CrossRefPubMedPubMedCentral

Fredholm, H., Eaker, S., Frisell, J., Holmberg, L., Fredriksson, I., & Lindman, H. (2009). Breast cancer in young women: poor survival despite intensive treatment. PloS One, 4(11), e7695. doi:10.1371/journal.pone.0007695.CrossRefPubMedPubMedCentral

Golshan, M., Miron, A., Nixon, A. J., Garber, J. E., Cash, E. P., Iglehart, J. D., & Wong, J. S. (2006). The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. American Journal of Surgery, 192(1), 58–62. doi:10.1016/j.amjsurg.2005.12.005.CrossRefPubMed

Gray, S. W., Hicks-Courant, K., Cronin, A., Rollins, B. J., & Weeks, J. C. (2014). Physicians’ attitudes about multiplex tumor genomic testing. Journal of Clinical Oncology, 32(13), 1317–1323. doi:10.1200/JCO.2013.52.4298.CrossRefPubMedPubMedCentral

Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., & Genomics (2013). ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine, 15(7), 565–574. doi:10.1038/gim.2013.73.CrossRefPubMedPubMedCentral

Green, R. C., Goddard, K. A., Jarvik, G. P., Amendola, L. M., Appelbaum, P. S., Berg, J. S., et al. (2016). Clinical sequencing exploratory research consortium: accelerating evidence-based practice of genomic medicine. American Journal of Human Genetics, 98(6), 1051–1066. doi:10.1016/j.ajhg.2016.04.011.CrossRefPubMedPubMedCentral

Guba, E. G., & Lincoln, Y. S. (1994). Competing paradigms in qualitative research. In N. K. Denzin & Y. S. Lincoln (Eds.), Handbook of qualitative research (pp. 105–117). Thousand Oaks: Sage.

Heemskerk-Gerritsen, B. A., Rookus, M. A., Aalfs, C. M., Ausems, M. G., Collee, J. M., Jansen, L., et al. (2015). Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. International Journal of Cancer, 136(3), 668–677. doi:10.1002/ijc.29032.PubMed

Hitch, K., Joseph, G., Guiltinan, J., Kianmahd, J., Youngblom, J., & Blanco, A. (2014). Lynch syndrome patients’ views of and preferences for return of results following whole exome sequencing. Journal of Genetic Counseling, 23(4), 539–551. doi:10.1007/s10897-014-9687-6.CrossRefPubMedPubMedCentral

Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277–1288. doi:10.1177/1049732305276687.CrossRefPubMed

Ingham, S. L., Sperrin, M., Baildam, A., Ross, G. L., Clayton, R., Lalloo, F., et al. (2013). Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Research and Treatment, 142(3), 611–618. doi:10.1007/s10549-013-2765-x.CrossRefPubMed

Institute of Medicine (2001). Crossing the quality chasm: A new health system for the 21st century. Washington, D.C.: National Academies Press.

Jamal, S. M., Yu, J. H., Chong, J. X., Dent, K. M., Conta, J. H., Tabor, H. K., & Bamshad, M. J. (2013). Practices and policies of clinical exome sequencing providers: analysis and implications. American Journal of Medical Genetics. Part A, 161A(5), 935–950. doi:10.1002/ajmg.a.35942.CrossRefPubMed

Janatova, M., Kleibl, Z., Stribrna, J., Panczak, A., Vesela, K., Zimovjanova, M., et al. (2013). The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. Cancer Epidemiology, Biomarkers & Prevention, 22(12), 2323–2332. doi:10.1158/1055-9965.epi-13-0745-t.CrossRef

Johnson, R. H., Chien, F. L., & Bleyer, A. (2013). Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA, 309(8), 800–805. doi:10.1001/jama.2013.776.CrossRefPubMed

Kaphingst, K. A., McBride, C. M., Wade, C., Alford, S. H., Brody, L. C., & Baxevanis, A. D. (2010). Consumers’ use of web-based information and their decisions about multiplex genetic susceptibility testing. Journal of Medical Internet Research, 12(3), e41. doi:10.2196/jmir.1587.CrossRefPubMedPubMedCentral

Kaphingst, K. A., Ivanovich, J., Biesecker, B. B., Dresser, R., Seo, J., Dressler, L. G., & Goodman, M. S. (2016). Preferences for return of incidental findings from genome sequencing among women diagnosed with breast cancer at a young Age. Clinical Genetics, 89(3), 378–384. doi:10.1111/cge.12597.CrossRefPubMed

Leventhal, K. G., Tuong, W., Peshkin, B. N., Salehizadeh, Y., Fishman, M. B., Eggly, S., et al. (2013). “Is it really worth it to get tested?”: primary care patients’ impressions of predictive SNP testing for colon cancer. Journal of Genetic Counseling, 22(1), 138–151. doi:10.1007/s10897-012-9530-x.CrossRefPubMed

Manolio, T. A., Chisholm, R. L., Ozenberger, B., Roden, D. M., Williams, M. S., Wilson, R., et al. (2013). Implementing genomic medicine in the clinic: the future is here. Genetics in Medicine, 15(4), 258–267. doi:10.1038/gim.2012.157.CrossRefPubMedPubMedCentral

Mardis, E. R. (2008). The impact of next-generation sequencing technology on genetics. Trends in Genetics, 24(3), 133–141. doi:10.1016/j.tig.2007.12.007.CrossRefPubMed

Matsui, K., Lie, R. K., Kita, Y., & Ueshima, H. (2008). Ethics of future disclosure of individual risk information in a genetic cohort study: a survey of donor preferences. Journal of Epidemiology, 18(5), 217–224.CrossRefPubMedPubMedCentral

Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., et al. (2013). Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute, 105(11), 812–822. doi:10.1093/jnci/djt095.CrossRefPubMed

McGuire, A. L., & Lupski, J. R. (2010). Personal genome research : what should the participant be told? Trends in Genetics, 26(5), 199–201. doi:10.1016/j.tig.2009.12.007.CrossRefPubMedPubMedCentral

McLaughlin, H. M., Ceyhan-Birsoy, O., Christensen, K. D., Kohane, I. S., Krier, J., Lane, W. J., & MedSeq, P. (2014). A systematic approach to the reporting of medically relevant findings from whole genome sequencing. BMC Medical Genetics, 15, 134. doi:10.1186/s12881-014-0134-1.CrossRefPubMedPubMedCentral

Murphy, J., Scott, J., Kaufman, D., Geller, G., LeRoy, L., & Hudson, K. (2008). Public expectations for return of results from large-cohort genetic research. The American Journal of Bioethics, 8(11), 36–43. doi:10.1080/15265160802513093.CrossRefPubMedPubMedCentral

O’Daniel, J., & Haga, S. B. (2011). Public perspectives on returning genetics and genomics research results. Public Health Genomics, 14, 346–355. doi:10.1159/000324933.CrossRefPubMedPubMedCentral

O’Neill, S. C., Lipkus, I. M., Sanderson, S. C., Shepperd, J., Docherty, S., & McBride, C. M. (2013). Motivations for genetic testing for lung cancer risk among young smokers. Tobacco Control, 22(6), 406–411. doi:10.1136/tobaccocontrol-2011-050306.CrossRefPubMed

Pasche, B., & Absher, D. (2011). Whole-genome sequencing: a step closer to personalized medicine. JAMA, 305(15), 1596–1597. doi:10.1001/jama.2011.484.CrossRefPubMed

Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., et al. (2006). ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nature Genetics, 38(8), 873–875. doi:10.1038/ng1837.CrossRefPubMed

Riedl, C. C., Slobod, E., Jochelson, M., Morrow, M., Goldman, D. A., Gonen, M., & Ulaner, G. A. (2014). Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. Journal of Nuclear Medicine, 55(10), 1578–1583. doi:10.2967/jnumed.114.143297.CrossRefPubMedPubMedCentral

Rutten, L. J., Arora, N. K., Bakos, A. D., Aziz, N., & Rowland, J. (2005). Information needs and sources of information among cancer patients: a systematic review of research (1980–2003). Patient Education and Counseling, 57(3), 250–261. doi:10.1016/j.pec.2004.06.006.CrossRefPubMed

Schmidlen, T. J., Wawak, L., Kasper, R., Garcia-Espana, J. F., Christman, M. F., & Gordon, E. S. (2014). Personalized genomic results: analysis of informational needs. Journal of Genetic Counseling, 23(4), 578–587. doi:10.1007/s10897-014-9693-8.CrossRefPubMed

Selkirk, C. G., Weissman, S. M., Anderson, A., & Hulick, P. J. (2013). Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genetic Testing and Molecular Biomarkers, 17(3), 219–225. doi:10.1089/gtmb.2012.0165.CrossRefPubMed

Sharp, R. R. (2011). Downsizing genomic medicine: approaching the ethical complexity of whole-genome sequencing by starting small. Genetics in Medicine, 13(3), 191–194. doi:10.1097/GIM.0b013e31820f603f.CrossRefPubMed

Sieh, W., Rothstein, J. H., McGuire, V., & Whittemore, A. S. (2014). The role of genome sequencing in personalized breast cancer prevention. Cancer Epidemiology, Biomarkers & Prevention, 23(11), 2322–2327. doi:10.1158/1055-9965.epi-14-0559.CrossRef

Tabor, H. K., Stock, J., Brazg, T., McMillin, M. J., Dent, K. M., Yu, J. H., et al. (2012). Informed consent for whole genome sequencing: a qualitative analysis of participant expectations and perceptions of risks, benefits, and harms. American Journal of Medical Genetics. Part A, 158A(6), 1310–1319. doi:10.1002/ajmg.a.35328.CrossRefPubMedPubMedCentral

Taplin, S. H., Anhang Price, R., Edwards, H. M., Foster, M. K., Breslau, E. S., Chollette, V., et al. (2012). Introduction: Understanding and influencing multilevel factors across the cancer care continuum. Journal of the National Cancer Institute. Monographs, 2012(44), 2–10. doi:10.1093/jncimonographs/lgs008.CrossRefPubMedPubMedCentral

Trujillano, D., Weiss, M. E., Schneider, J., Koster, J., Papachristos, E. B., Saviouk, V., et al. (2015). Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer. The Journal of Molecular Diagnostics, 17(2), 162–170. doi:10.1016/j.jmoldx.2014.11.004.CrossRefPubMed

Wright, M. F., Lewis, K. L., Fisher, T. C., Hooker, G. W., Emanuel, T. E., Biesecker, L. G., & Biesecker, B. B. (2014). Preferences for results delivery from exome sequencing/genome sequencing. Genetics in Medicine, 16(6), 442–447. doi:10.1038/gim.2013.170.CrossRefPubMed

Yauch, R. L., & Settleman, J. (2012). Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Current Opinion in Genetics & Development, 22(1), 45–49. doi:10.1016/j.gde.2012.01.003.CrossRef

Yu, J. H., Crouch, J., Jamal, S. M., Bamshad, M. J., & Tabor, H. K. (2014). Attitudes of non-African American focus group participants toward return of results from exome and whole genome sequencing. American Journal of Medical Genetics. Part A, 164A(9), 2153–2160. doi:10.1002/ajmg.a.36610.CrossRefPubMed

Zardavas, D., Baselga, J., & Piccart, M. (2013). Emerging targeted agents in metastatic breast cancer. Nature Reviews. Clinical Oncology, 10(4), 191–210. doi:10.1038/nrclinonc.2013.29.CrossRefPubMed

Title: Information Topics of Greatest Interest for Return of Genome Sequencing Results among Women Diagnosed with Breast Cancer at a Young Age
Authors: Joann Seo
Jennifer Ivanovich
Melody S. Goodman
Barbara B. Biesecker
Kimberly A. Kaphingst
Publication date: 01-06-2017
Publisher: Springer US
Published in: Journal of Genetic Counseling / Issue 3/2017
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-016-0006-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Information Topics of Greatest Interest for Return of Genome Sequencing Results among Women Diagnosed with Breast Cancer at a Young Age

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

The Subjective Experience of Patients Diagnosed with Hereditary Hemorrhagic Telangiectasia: a Qualitative Study

Standards for the Reporting of Genetic Counseling Interventions in Research and Other Studies (GCIRS): an NSGC Task Force Report

The Dynamics of a Genetic Counseling Peer Supervision Group

Parents’ Understanding of Genetics and Heritability

Genetic Counseling Dilemmas for a Patient with Sporadic Amyotrophic Lateral Sclerosis, Frontotemporal Degeneration & Parkinson’s Disease

A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes